Suven Life Sciences misses target for Alzheimers molecule SUVN 502

Suven Life Sciences has missed their target for SUVN 502 - a molecule which they were banking on for Alzheimers and outlicensing opportunity. Venkat Jasti, chairman and CEO of Suven Life Sciences shared more details and the future course of action.